Cardinal Partners

Cardinal Partners is a venture capital firm founded in 1996 and headquartered in Princeton, New Jersey, with additional offices in Laguna Beach, California, and Wayne, Pennsylvania. The firm specializes in early-stage investments primarily within the healthcare sector, focusing on healthcare information technology, medical technology, life sciences, and related medical products and devices. Cardinal Partners typically invests between $6 million and $12 million in its portfolio companies, often taking the lead role in initial financing rounds. While it primarily targets companies based in the United States, it emphasizes investments in the Mid Atlantic region. The firm aims to support high-growth companies that align with its investment strategy in healthcare and technology sectors.

Kent Marquardt

General Partner

John J. Park

Partner and CFO

58 past transactions

Intellicare Group

Venture Round in 2022
Intellicare Group is a health maintenance organization based in the Philippines that specializes in delivering managed healthcare services. Established in 1995 and headquartered in Makati City, the company operates a network of outpatient multi-specialty clinics and offers comprehensive health maintenance programs. It provides third-party administration services tailored for corporate clients and small to medium-sized enterprises. With regional offices in key cities such as Bacolod, Calamba, Cebu, and Davao, as well as several satellite offices across the country, Intellicare Group emphasizes a systematic and preventive approach to health management. The organization has been a subsidiary of Fullerton Healthcare Corporation Limited since May 2018.

Vividion Therapeutics

Series B in 2019
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Cureatr

Venture Round in 2018
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.

Prealize Health

Series A in 2017
Prealize Health, founded in 2015 and located in Palo Alto, California, leverages machine learning to proactively transform healthcare. The company specializes in identifying potential high-cost patients before they experience significant health events, enabling timely medical interventions. By collaborating with clinician teams, Prealize targets specific interventions that enhance care quality and manage costs effectively. Its predictive analytics empower health plans, employers, and providers to foresee future risks, facilitating better decision-making in patient care. Through this innovative approach, Prealize Health aims to improve overall health outcomes and promote healthier living.

Vividion Therapeutics

Series A in 2017
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Vividion Therapeutics

Series A in 2016
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

lifeIMAGE

Series D in 2015
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Ivenix

Venture Round in 2015
Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.

Cureatr

Series B in 2015
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.

lifeIMAGE

Venture Round in 2015
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

aTyr Pharma

Series E in 2015
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Teladoc

Series C in 2014
Teladoc is a healthcare organization dedicated to improving access to medical services and enhancing patient experiences globally. It offers a range of integrated clinical solutions, including telehealth, expert medical consultations, artificial intelligence, and analytics, aimed at providing high-quality care at lower costs. With a workforce of over 2,000 employees, Teladoc operates in 125 countries and supports communication in more than 20 languages. The company collaborates with employers, hospitals, health systems, and insurers to revolutionize care delivery, ensuring that patients can access medical professionals anytime, day or night. Through its innovative approach, Teladoc seeks to improve health outcomes for individuals worldwide.

Privia Health

Private Equity Round in 2014
Privia Health, LLC is a physician practice management and population health technology company based in Arlington, Virginia. Established in 2007, it focuses on enhancing healthcare delivery through its collaboration with physician groups, health plans, and national payers. Privia Health operates a high-performance physician group and an accountable care organization, utilizing a proprietary cloud-based technology platform to improve patient engagement and promote wellness. The company's approach aligns reimbursements with quality outcomes, aiming to keep populations healthy and effectively manage diseases. Privia Health has formed strategic alliances with organizations such as Premier Medical Group and Children’s Health, further strengthening its commitment to delivering high-value care. As a subsidiary of Brighton Health Services Holdings Corp, Privia Health continues to innovate in the healthcare sector.

Cureatr

Series A in 2013
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.

aTyr Pharma

Series D in 2013
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Vitals

Series C in 2013
Vitals Consumer Services, LLC specializes in healthcare transparency and engagement solutions for consumers, employers, and health plans. Established in 2006 and headquartered in Lyndhurst, New Jersey, the company offers various tools to assist individuals in navigating their healthcare options. Among its key offerings are an online search tool for finding doctors, a healthcare transparency platform that clarifies health benefits and care choices, and an incentive program that rewards patients for selecting cost-effective care. Vitals serves over 280 million people annually, helping them make informed decisions about their healthcare. As of August 2018, Vitals operates as a subsidiary of WebMD Health Corp, with additional locations in New York, Tulsa, Westborough, and Bedford.

lifeIMAGE

Series C in 2013
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

QPID

Series A in 2013
QPID Health, Inc. is a healthcare IT software company that provides a health record intelligence platform designed to enhance the use of electronic health records (EHRs) in clinical settings. The company's flagship product, the Queriable Programmable Inference Dossier (QPID), enables healthcare institutions to generate clinician-directed queries, analytics, and reporting in real time, facilitating improved decision-making at the point of care. Developed initially at Massachusetts General Hospital, the QPID platform utilizes natural language processing and machine learning to deliver context-sensitive information from patient records, thereby increasing clinician productivity and supporting better patient outcomes. QPID Health is headquartered in Boston, Massachusetts, with an additional location in San Diego, California. The company aims to maximize the value of EHR investments and streamline quality reporting and clinical registry submissions, ultimately helping healthcare providers reduce costs and meet quality goals.

Vascular Pharmaceuticals

Series A in 2012
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.

Awarepoint

Venture Round in 2012
Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.

lifeIMAGE

Series B in 2011
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Medley Health

Series A in 2011
Medley Health is an innovative, entrepreneurial, technology-driven company. It's backed by top-tier investors and a management team with deep business expertise in healthcare, Internet and web services, as well as next-generation communications technologies.

Verastem

Series C in 2011
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.

Teladoc

Series A in 2011
Teladoc is a healthcare organization dedicated to improving access to medical services and enhancing patient experiences globally. It offers a range of integrated clinical solutions, including telehealth, expert medical consultations, artificial intelligence, and analytics, aimed at providing high-quality care at lower costs. With a workforce of over 2,000 employees, Teladoc operates in 125 countries and supports communication in more than 20 languages. The company collaborates with employers, hospitals, health systems, and insurers to revolutionize care delivery, ensuring that patients can access medical professionals anytime, day or night. Through its innovative approach, Teladoc seeks to improve health outcomes for individuals worldwide.

Awarepoint

Series F in 2011
Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.

Fluidnet

Series C in 2011
Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Verastem

Series B in 2011
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.

lifeIMAGE

Series B in 2011
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Awarepoint

Venture Round in 2010
Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.

Verastem

Series A in 2010
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.

aTyr Pharma

Series C in 2010
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Fluidnet

Series B in 2010
Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Awarepoint

Series E in 2010
Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.

Teladoc

Series A in 2009
Teladoc is a healthcare organization dedicated to improving access to medical services and enhancing patient experiences globally. It offers a range of integrated clinical solutions, including telehealth, expert medical consultations, artificial intelligence, and analytics, aimed at providing high-quality care at lower costs. With a workforce of over 2,000 employees, Teladoc operates in 125 countries and supports communication in more than 20 languages. The company collaborates with employers, hospitals, health systems, and insurers to revolutionize care delivery, ensuring that patients can access medical professionals anytime, day or night. Through its innovative approach, Teladoc seeks to improve health outcomes for individuals worldwide.

Inspired Technologies

Series B in 2009
Inspired Technologies (North Huntingdon, PA) a commercial-stage medical device company focused on auto-titration of oxygen delivery for COPD patients.

aTyr Pharma

Series C in 2009
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Awarepoint

Series D in 2008
Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.

CodeRyte

Series D in 2008
CodeRyte is the premier provider of computer-assisted coding and clinical data extraction solutions for the healthcare industry. Their sophisticated technology streamlines the coding process and identifies clinically relevant information from medical records. Their clients secure their rightful reimbursement, enhance compliance and efficiency through computer-assisted coding. CodeRyte's data extraction solutions analyze the language of physician narratives and elevate previously undiscovered data for critical treatment and business decisions. Many of the nation's top physician practices, billing companies and academic medical centers rely on CodeRyte as the centerpiece of their coding and data mining operations.

AxoGen

Post in 2007
AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

Inspired Technologies

Series A in 2007
Inspired Technologies (North Huntingdon, PA) a commercial-stage medical device company focused on auto-titration of oxygen delivery for COPD patients.

aTyr Pharma

Series B in 2007
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Bioconnect Systems

Series A in 2007
Bioconnect Systems, established in 2006 and headquartered in Fort Washington, Pennsylvania, specializes in developing innovative surgical implants and techniques aimed at creating controlled vascular connections. The company's flagship product, the Optiflow family of sutureless anastomotic connectors, offers a rapid and reliable solution for connecting blood vessels. These advancements significantly enhance the performance of arteriovenous fistulae and vascular access grafts, particularly benefiting patients with renal diseases by streamlining the vessel connection process.

Melinta

Series C in 2006
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

CodeRyte

Series C in 2006
CodeRyte is the premier provider of computer-assisted coding and clinical data extraction solutions for the healthcare industry. Their sophisticated technology streamlines the coding process and identifies clinically relevant information from medical records. Their clients secure their rightful reimbursement, enhance compliance and efficiency through computer-assisted coding. CodeRyte's data extraction solutions analyze the language of physician narratives and elevate previously undiscovered data for critical treatment and business decisions. Many of the nation's top physician practices, billing companies and academic medical centers rely on CodeRyte as the centerpiece of their coding and data mining operations.

Sirtris Pharmaceuticals

Series B in 2005
Sirtris Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of proprietary, orally available small molecule drugs aimed at treating diseases related to aging. The company's research primarily focuses on metabolic disorders, including Type 2 Diabetes. By leveraging innovative approaches in drug development, Sirtris seeks to address the growing healthcare challenges associated with age-related diseases.

Roving Planet

Series C in 2005
Roving Planet, Inc. provides network access control and management solutions for enterprise networks. Its products provide a secure network environment by managing and controlling users, endpoints, connections, and sessions. The company serves enterprise, manufacturing, health, higher education, k-12, and aerospace government industries. Roving Planet, Inc. was founded in 2001 and is headquartered in Westminster, Colorado.

Sirtris Pharmaceuticals

Series A in 2004
Sirtris Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of proprietary, orally available small molecule drugs aimed at treating diseases related to aging. The company's research primarily focuses on metabolic disorders, including Type 2 Diabetes. By leveraging innovative approaches in drug development, Sirtris seeks to address the growing healthcare challenges associated with age-related diseases.

Momenta Pharmaceuticals

Series C in 2004
Biotechnology company specializing in the characterization and process engineering of complex molecules

Alnylam Pharmaceuticals

Venture Round in 2003
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Its innovative pipeline targets a range of serious conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system and ocular diseases. The company has successfully brought several RNAi therapeutics to market, including ONPATTRO for hereditary transthyretin-mediated amyloidosis and GIVLAARI for acute hepatic porphyria. Additionally, Alnylam is advancing other investigational therapies, such as givosiran for acute hepatic porphyria and lumasiran for primary hyperoxaluria type 1. The company collaborates with various partners, including Sanofi Genzyme and Vir Biotechnology, to enhance its research and development efforts. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals aims to transform treatment approaches for patients with rare and debilitating diseases through its RNAi technology.

Momenta Pharmaceuticals

Series B in 2003
Biotechnology company specializing in the characterization and process engineering of complex molecules

NexCura

Series C in 2002
NexCura specializes in online decision support services tailored for patient communities, offering applications and custom services through an application service provider model. The company's platforms facilitate the collection of comprehensive clinical data, enhancing communication between patients and their physicians. It provides valuable resources such as patient education and market research services. Additionally, NexCura's NexProfiler tools assist in pre-treatment decision-making by integrating clinical evidence with personal concerns and the unique clinical circumstances of individual patients. This aggregated data serves to benefit healthcare organizations, pharmaceutical companies, physicians, and patients alike.

IntelliCare

Series B in 2002
Providing 24-hour healthcare these days is a tough balancing act. Don't perform without a safety net you can trust. At IntelliCare, they know the ropes. They're a management company for medical call centers, and they work closely with health systems, provider networks and physician groups to make their operations a success. They offer experience, flexibility, commitment -- and a wide range of 24-hour telephonic and Web-based medical call center services that let you focus on what you do best. Making people feel better.

IntelliCare

Venture Round in 2000
Providing 24-hour healthcare these days is a tough balancing act. Don't perform without a safety net you can trust. At IntelliCare, they know the ropes. They're a management company for medical call centers, and they work closely with health systems, provider networks and physician groups to make their operations a success. They offer experience, flexibility, commitment -- and a wide range of 24-hour telephonic and Web-based medical call center services that let you focus on what you do best. Making people feel better.

IC-USA

Series B in 2000
IC·USA is dedicated to improving outcomes for critical care patients.

Pointshare

Series C in 1999
Pointshare is a national leader in connecting local healthcare communities with secure, online business services that enhance communication, create efficiencies, and improve the delivery of care. Pointshare is the only company that has developed the technology, infrastructure, and hands-on service to create a proven, practical solution for automating the day-to-day business transactions of healthcare.

Pointshare

Series B in 1999
Pointshare is a national leader in connecting local healthcare communities with secure, online business services that enhance communication, create efficiencies, and improve the delivery of care. Pointshare is the only company that has developed the technology, infrastructure, and hands-on service to create a proven, practical solution for automating the day-to-day business transactions of healthcare.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.